A Novel Model of Cardiac Remodeling by a Minimally Invasive Aortic Regurgitation Surgery in Mice

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2025-09-16 DOI:10.1016/j.jacbts.2025.101324

Xiang Li PhD , Jian Wu PhD , Le Kang PhD , Xuan Li PhD , Weijiang Tan PhD , Shuang Zheng MS , Jianguo Jia BS , Shijun Wang PhD , Chunjie Yang BS , Xuecong Ren BS , Honghua Chen BS , Hui Gong PhD , Kuan Cheng PhD , Huan Sun MD, PhD , Fenghua Yang PhD , Yunzeng Zou MD, PhD

{"title":"A Novel Model of Cardiac Remodeling by a Minimally Invasive Aortic Regurgitation Surgery in Mice","authors":"Xiang Li PhD , Jian Wu PhD , Le Kang PhD , Xuan Li PhD , Weijiang Tan PhD , Shuang Zheng MS , Jianguo Jia BS , Shijun Wang PhD , Chunjie Yang BS , Xuecong Ren BS , Honghua Chen BS , Hui Gong PhD , Kuan Cheng PhD , Huan Sun MD, PhD , Fenghua Yang PhD , Yunzeng Zou MD, PhD","doi":"10.1016/j.jacbts.2025.101324","DOIUrl":null,"url":null,"abstract":"<div><div>Although the prevalence of aortic regurgitation (AR), which causes eccentric remodeling and valvular heart disease (VHD), is increasing, suitable animal research models remain lacking. To address this issue, we established the first efficient, real-time visualized minimally invasive aortic regurgitation surgery mouse model by performing echocardiography-guided aortic valve tear using a modified insulin needle. The clinically relevant features of this AR model were verified by multimodal analysis, and feature genes closely associated with AR-induced VHD were obtained by time series analysis in conjunction with weighted gene co-expression network analysis. The results may provide comprehensive insights into the mechanistic study and potential therapeutic targets of AR-induced VHD.</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 10","pages":"Article 101324"},"PeriodicalIF":8.4000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X25002748","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Although the prevalence of aortic regurgitation (AR), which causes eccentric remodeling and valvular heart disease (VHD), is increasing, suitable animal research models remain lacking. To address this issue, we established the first efficient, real-time visualized minimally invasive aortic regurgitation surgery mouse model by performing echocardiography-guided aortic valve tear using a modified insulin needle. The clinically relevant features of this AR model were verified by multimodal analysis, and feature genes closely associated with AR-induced VHD were obtained by time series analysis in conjunction with weighted gene co-expression network analysis. The results may provide comprehensive insights into the mechanistic study and potential therapeutic targets of AR-induced VHD.

查看原文本刊更多论文

一种新的小鼠微创主动脉反流手术心脏重塑模型。

主动脉反流（AR）可导致偏心重塑和瓣膜性心脏病（VHD），尽管其发病率正在增加，但仍然缺乏合适的动物研究模型。为了解决这个问题，我们建立了第一个有效的、实时可视化的微创主动脉瓣反流手术小鼠模型，通过使用改良的胰岛素针进行超声心动图引导主动脉瓣撕裂。通过多模态分析验证该AR模型的临床相关特征，通过时间序列分析结合加权基因共表达网络分析获得与AR诱导VHD密切相关的特征基因。该结果可能为ar诱导的VHD的机制研究和潜在的治疗靶点提供全面的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.